Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
Condition: Central Precocious Puberty
MeSH terms: Puberty, Precocious
Intervention: Triptorelin
Intervention description: Powder and solution for solution for injection
Intervention MeSH terms: Triptorelin Pamoate
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 44.0
Sex: All
Minimum age: 2 Years
Maximum age: 9 Years
Healthy volunteers: No

Summary:

      The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22.5 mg
      6-month formulation in 44 patients suffering from central precocious puberty. The total study
      duration per patient will be 12 months (48 weeks).
    

Eligibility criteria:

        Inclusion criteria:

          1. Onset of development of sex characteristics before 8 and 9 years in girls and boys,
             respectively (breast development in girls or testicular enlargement in boys according
             to the Tanner method), and candidate to receive at least 12 months of GnRH agonist
             therapy after study entry.

          2. Aged 2-8 years inclusive (i.e. < 9 years) for girls and 2-9 years inclusive (i.e. < 10
             years) for boys at initiation of triptorelin treatment.

          3. Initiation of triptorelin treatment at the latest 18 months after onset of the first
             signs of precocious puberty.

          4. Difference (Δ) bone age (Greulich and Pyle method) - chronological age ≥ 1 year.

          5. Pubertal-type LH response 30 minutes following a GnRH agonist stimulation test before
             treatment initiation (leuprolide acetate 20 μg/kg SC) ≥ 6 IU/L.

          6. Clinical evidence of puberty, defined as Tanner Staging ≥ 2 for breast development for
             girls and testicular volume ≥ 4 mL (cc) for boys.

          7. Informed consent signed by one parent or both parents (as per local requirements), by
             the liable parent or by the legal guardian (when applicable); assent signed by the
             child if ≥ 7 years.

        Non-inclusion criteria:

          1. Gonadotropin-independent (peripheral) precocious puberty: extra pituitary secretion of
             gonadotropins or gonadotropin-independent gonadal or adrenal sex steroid secretion.

          2. Non-progressing isolated premature thelarche.

          3. Presence of an unstable intracranial tumour or an intracranial tumour requiring
             neurosurgery or cerebral irradiation. Patients with hamartomas not requiring surgery
             are eligible.

          4. Evidence of renal (creatinine > 2 x ULN) or hepatic impairment (bilirubin or ASAT > 3
             x ULN).

          5. Any other condition or chronic illness or treatment possibly interfering with growth
             or other study endpoints (e.g. chronic steroid use [except mild topical steroids],
             renal failure, diabetes, moderate to severe scoliosis, previously treated intracranial
             tumour).

          6. Prior or current therapy with a GnRH agonist, medroxyprogesterone acetate, growth
             hormone or insulin-like growth factor-1 (IGF 1).

          7. Major medical or psychiatric illness that could interfere with study visits.

          8. Diagnosis of short stature, i.e. > 2.25 SD below the mean height for age.

          9. Positive pregnancy test.

         10. Known hypersensibility to any of the test materials or related compounds.

         11. Use of anticoagulants (heparin and coumarin derivatives).